Vaxil Bio Ltd.
VXLLF
$0.10
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 120.10K | 129.20K | 133.20K | 112.60K | 52.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.40K | 133.50K | 137.50K | 128.90K | 83.20K |
| Operating Income | -124.40K | -133.50K | -137.50K | -128.90K | -83.20K |
| Income Before Tax | -53.00K | -64.90K | -121.60K | -115.80K | -81.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.05 | -0.06 | -0.12 | -0.12 | -0.08 |
| Earnings from Discontinued Operations | 4.30K | -5.20K | -14.60K | -14.60K | -14.60K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.60K | -70.00K | -136.20K | -130.40K | -95.60K |
| EBIT | -124.40K | -133.50K | -137.50K | -128.90K | -83.20K |
| EBITDA | -- | -- | -- | -- | 23.20K |
| EPS Basic | -0.02 | -0.03 | -0.05 | -0.05 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | -0.02 | -0.03 | -0.05 | -0.05 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.03 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 10.96M | 10.96M | 10.96M | 10.96M | 10.96M |
| Average Diluted Shares Outstanding | 10.96M | 10.96M | 10.96M | 10.96M | 10.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |